La vendita allo scoperto per scPharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di scPharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

scPharmaceuticals (NASDAQ:SCPH) Azioni, Report sulle vendite allo scoperto

scPharmaceuticals

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

scPharmaceuticals Inc

Northland Capital Markets analyst Mike Grondahl maintains Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) with a Outperform and raises the price target from $185 to $300.

News

Price Target

Analyst Ratings

SEZL

Northland Capital Markets Maintains Outperform on Sezzle, Raises Price Target to $300

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday.
Shares of Sony Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) rose sharply during Thursday's session after reporting better-than-expected second-quarter earnings and r<a href="https://www.benzinga.com/news/earnings/24/11/41841647/sonys-q2-profit-surges-on-gaming-and-sensor-gains-but-ps5-sales-decline-raises-full-year-outlook">aising FY24 revenue outlook</a>.
Sony Group reported fiscal second-quarter 2024 consolidated sales growth of 3% year-on-year to $19.44 billion (2.91 trillion Japanese yen), missing the analyst consensus estimate of $19.62 billion. EPS of $0.37 (55.74 yen) beat the analyst consensus estimate of $0.27.
Sony shares jumped 9.4% to $19.98 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares surged 67.7% to $40.84.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) shares jumped 51.7% to $380.00 after the company reported a year-over-year increase in third-quarter financial results, raised its FY24 guidance, and issued FY25 adjusted EPS guidance above estimates.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) surged 44% to $79.89 after the company reported better-than-expected quarterly financial results.</li>
<li>indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) gained 43.3% to $4.9200 after the company reported better-than-expected third-quarter financial results.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) gained 37.8% to $59.87 following better-than-expected second-quarter financial results.</li>
<li>Fortrea Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) rose 32% to $23.82 after the company issued FY24 revenue guidance above estimates.</li>
<li>Axon Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) gained 26.3% to $591.89 after the company reported better-than-expected third-quarter financial results and issued current-quarter revenue guidance above estimates.</li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) gained 20.4% to $314.49 following upbeat quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 19.8% to $12.78. The company announced a 20 MW utility deal with FPM Development and Baird maintained an Outperform rating on the stock.</li>
<li>Tempus AI, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NYSE">TEM</a>) gained 18.8% to $67.50.</li>
<li>AAON, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) shares rose 15.7% to $137.83 after the company reported better-than-expected quarterly financial results. Also, Baird raised its price target on the stock from $130 to $138 and maintained an Outperform rating.</li>
<li>Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 14.4% to $84.25 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates.</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) gained 13.3% to $37.00 after the company reported better-than-expected quarterly financial results.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 8.3% to $321.66. The stock has continued to gain following the US presidential election.</li>
<li>SharkNinja, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) gained 7.1% to $102.80.</li>
<li>Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) gained 5.8% to $184.24 after the company reported better-than-expected third-quarter adjusted EPS results. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

AAON

AXON

DOCS

EXPE

FTRE

INDI

INOD

LITE

Sony Group Corporation American Depositary Shares

SONY

TOST

TSLA

UPST

Sony Posts Upbeat Earnings, Joins Tesla, Upstart, Doximity, Fortrea, Axon Enterprise And Other Big Stocks Moving Higher On Friday

Northland Capital Markets analyst Greg Gibas maintains GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) with a Outperform and raises the price target from $16 to $37.

Northland Capital Markets Maintains Outperform on GEO Group, Raises Price Target to $37

WIIM

COIN

Coinbase shares are trading higher amid the election of President-Elect Trump as his policies could be favorable towards the crypto market.

Barclays analyst Mario Lu maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Overweight and lowers the price target from $55 to $53.

MTCH

Barclays Maintains Overweight on Match Group, Lowers Price Target to $53

BBWI

Bath & Body Works shares are trading lower after Barclays downgraded the stock from Equal-Weight to Underweight and lowered its price target from $31 to $28.

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $171 to $190.

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $190

COST

Costco shares are trading higher after the company reported better-than-expected Q3 Financials.

Speculation has arisen regarding Charles Hoskinson, the co-founder of Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), potentially serving as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41785767/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">cryptocurrency policy advisor</a> in the administration of president Donald Trump.
What Happened: This speculation comes on the heels of recent posts and statements from various figures within the crypto community, hinting at a possible alignment of interests between Hoskinson and the Trump campaign, particularly with Trump&#8217;s recent ventures into the cryptocurrency space.
The buzz started when Rick McCracken, a notable figure in the Cardano community, expressed <a href="https://x.com/TamaraHaasen/status/1854865475194294383">hope</a> on X (formerly Twitter) that the Trump-Vance administration might consider Hoskinson for such a role.
This suggestion was not made in a vacuum; Hoskinson has previously <a href="https://x.com/RobertKennedyJr/status/1780726997020508562">endorsed</a> Robert F. Kennedy Jr., who has since joined Trump&#8217;s team, indicating a potential pathway for dialogue or collaboration.
Hoskinson, known for his vocal criticism of the current administration&#8217;s crypto policies, has often highlighted the lack of regulatory clarity and what he perceives as an adversarial stance against the crypto industry. 
His endorsement of RFK Jr. was seen as a move towards supporting candidates who promise a change in policy direction, focusing on healing national divisions and promoting economic freedom through decentralized technologies.
The crypto community&#8217;s interest in Hoskinson&#8217;s potential advisory role stems from his deep involvement in blockchain technology and his advocacy for a regulatory environment that fosters innovation rather than stifling it. 
His insights could be pivotal, especially given Trump&#8217;s family&#8217;s recent forays into decentralized finance (DeFi) projects, signaling a more crypto-friendly stance from the former president.
However, the path to such an appointment isn&#8217;t without hurdles.
Hoskinson&#8217;s criticisms of both major political parties for their handling of crypto regulations suggest that any advisory role would come with the expectation of pushing for significant policy reforms.
This could mean navigating the complex political landscape where crypto regulations are concerned, balancing between innovation and security.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41851865/bitcoin-to-200000-ethereum-to-10000-and-crypto-market-cap-to-4x-by-end-of-2025-says-standard-chartered">Bitcoin To $200,000, Ethereum To $10,000 And Crypto Market Cap To 4X By End Of 2025, Says Standard Chartered</a>
The discussion emerges as Cardano&#8217;s native token ADA has reclaimed its position as the ninth-largest cryptocurrency overall, and the seventh-largest when excluding stablecoins like Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) and USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>). 
The token has shown significant momentum, up 13% over the past 24 hours and 30% over the past 30 days, breaking above key technical resistance levels that have been closely watched by market analysts, <a href="https://x.com/cryptorecruitr/status/1854902966550942065">according</a> to a crypto analyst.
Technical analysis of ADA&#8217;s current movement shows parallels to previous market cycles, particularly in relation to Bitcoin halving events. 
Market data indicates ADA is currently trading approximately 201 days after the latest Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) halving, comparable to a similar breakout pattern observed in the previous cycle at 193 days post-halving.
The asset has demonstrated a notable separation from its 20-day moving average, currently showing a 14% divergence. 
Key resistance levels are identified at $0.47, aligned with the 50-week moving average, while analysts have outlined potential targets extending to $0.60-0.70 based on current pattern formations.
The timing of these speculations couldn&#8217;t be more intriguing, especially with the upcoming Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19. 
This event could serve as a platform for further discussions or announcements regarding the intersection of cryptocurrency and U.S. policy, potentially shedding light on how figures like Hoskinson might influence or be <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">influenced by political decisions.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41849213/crypto-queen-ruja-ignatova-onecoins-4-billion-fraud-mastermind-is-alive-and-in-south-africa-german-police-suspects">&#8216;Crypto Queen&#8217; Ruja Ignatova, OneCoin&#8217;s $4 Billion Fraud Mastermind, Is Alive And In South Africa, German Police Suspects</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$ETH

$USDC

$USDT

Cardano Up 13% As Speculation Around Charles Hoskinson As Trump Crypto Policy Advisor Bubbles

Barclays analyst Andrew Mok maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Overweight and lowers the price target from $396 to $392.

Barclays Maintains Overweight on HCA Healthcare, Lowers Price Target to $392

LFMD

LifeMD shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Rumors

AUTL

Watching Autolus Therapeutics; Shares Spike Higher As Traders Circulate Aucatzyl Is Now FDA Approved As A Treatment For Adults With Acute Lymphoblastic Leukemia

Barclays analyst Tim Long maintains Motorola Solns (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) with a Overweight and raises the price target from $467 to $529.

Barclays Maintains Overweight on Motorola Solns, Raises Price Target to $529

The S&amp;P 500 index surged past the 6,000-point milestone, setting fresh record highs, and small-cap stocks are poised for their best weekly performance since April 2024 as investor optimism surrounding the &#8220;Trump trade&#8221; continued to fuel a strong risk-on sentiment by the end of a <a href="https://www.benzinga.com/markets">wild week in the market</a>. 
All major U.S. indices posted modest gains in midday trading, with the Dow Jones Industrial Average leading slightly, soaring beyond the 44,000-point mark. The blue-chip index is set for its best weekly performance in over a year.
Friday's rise in the S&amp;P 500 was powered by the utilities and real estate sectors, which had lagged post-election. Tech stocks took a breather following Thursday's rally.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) surged 7%, pushing its weekly gains beyond 27% and propelling its market cap past $1 trillion. 
This move now places every "Magnificent Seven" tech stock in the trillion-dollar club, with the group's combined market cap topping $17 trillion.
Treasury yields held steady, while the dollar strengthened in response to the Federal Reserve's Thursday 25-basis-point rate <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41823887/powell-dismisses-talk-of-resignation-after-trump-victory-says-policy-is-still-res">cut to 4.5%-4.75%</a>.
Gold softened, eyeing its worst week since late May, as both silver and oil dropped over 2% on the day. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 0.8%, extending its weekly gains to over 11%, marking its best week since July.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,993.21</td>
<td>0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,998.81</td>
<td>0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,389.50</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,124.53</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 1:05 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110824&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.4% to $598.17.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.6% to $439.89.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) inched 0.1% higher to $514.10.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.3% to $237.08.</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, rising 1.8%. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports were: 
<ul>
<li>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>), up 0.5%, </li>
<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>), up 21%</li>
<li>Arista Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NASDAQ">ANET</a>), down 7%, </li>
<li>Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), down 7.5%, </li>
<li>Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>), up 6.7%, </li>
<li>EOG Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>), up 5.9%, </li>
<li>Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>), up over 9%, </li>
<li>The Trade Desk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), down over 4%, </li>
<li>Monster Beverage Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNST#NASDAQ">MNST</a>), up by 0.5%, </li>
<li>Axon Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>), up 25%, </li>
<li>Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>), down 4.4%, </li>
<li>Cloudfare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), down 6.2%, </li>
<li>Corpay Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>), up 6%, </li>
<li>Expedia Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NYSE">EXPE</a>), up over 6%, </li>
<li>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), up 13%, </li>
<li>Pinterest Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), down 17%, </li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), up 1.7%, </li>
<li>Insulet Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), up 12%, </li>
<li>News Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWS#NASDAQ">NWS</a>), up 3.6%, </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41848568/us-consumer-sentiment-rises-more-than-predicted-to-6-month-highs-inflation-expectations-hit-4-year-low">US Consumer Sentiment Rises More Than Predicted To 6-Month Highs, Inflation Expectations Hit 4-Year Low</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Sector ETFs

ETFs

ABNB

ANET

CPAY

SPDR Dow Jones Industrial Average ETF Trust

DKNG

FTNT

MNST

PINS

PODD

S&P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday?

ATHA

Althira Pharma shares are trading lower after the company reported worse-than-expected Q3 EPS results.

Barclays analyst Jared Shaw maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Overweight and raises the price target from $21 to $23.

Barclays Maintains Overweight on First Horizon, Raises Price Target to $23

Northland Capital Markets analyst Greg Gibas maintains CoreCivic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) with a Outperform and raises the price target from $17 to $32.

Northland Capital Markets Maintains Outperform on CoreCivic, Raises Price Target to $32

Whales with a lot of money to spend have taken a noticeably bearish stance on Lululemon Athletica.
Looking at options history for Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened trades with bullish expectations and 69% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $480,245 and 3, calls, for a total amount of $273,960.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $270.0 to $360.0 for Lululemon Athletica during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Lululemon Athletica stands at 827.88, with a total volume reaching 1,425.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lululemon Athletica, situated within the strike price corridor from $270.0 to $360.0, throughout the last 30 days.
<h3>Lululemon Athletica Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731090759_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LULU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$44.5</td>
<td>$42.0</td>
<td>$44.5</td>
<td>$270.00</td>
<td>$222.5K</td>
<td>587</td>
<td align="right">50</td>
</tr>
<tr>
<td>LULU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$21.5</td>
<td>$20.6</td>
<td>$21.5</td>
<td>$330.00</td>
<td>$126.8K</td>
<td>64</td>
<td align="right">60</td>
</tr>
<tr>
<td>LULU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$18.65</td>
<td>$18.5</td>
<td>$18.5</td>
<td>$290.00</td>
<td>$55.5K</td>
<td>1.6K</td>
<td align="right">296</td>
</tr>
<tr>
<td>LULU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$5.35</td>
<td>$4.85</td>
<td>$4.9</td>
<td>$270.00</td>
<td>$49.4K</td>
<td>785</td>
<td align="right">108</td>
</tr>
<tr>
<td>LULU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$18.7</td>
<td>$17.55</td>
<td>$18.7</td>
<td>$290.00</td>
<td>$43.0K</td>
<td>1.6K</td>
<td align="right">83</td>
</tr>
</tbody>
</table>

<h3>About Lululemon Athletica</h3>
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 700 company-owned stores in about 20 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
After a thorough review of the options trading surrounding Lululemon Athletica, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Lululemon Athletica</h3>
<ul>
<li>Trading volume stands at 249,671, with LULU's price up by 1.61%, positioned at $318.19.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>Expert Opinions on Lululemon Athletica</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $370.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Lululemon Athletica with a target price of $360. 
&#x2A; An analyst from Baird persists with their Outperform rating on Lululemon Athletica, maintaining a target price of $380. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lululemon Athletica options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

LULU

Unpacking the Latest Options Trading Trends in Lululemon Athletica

Financial giants have made a conspicuous bullish move on Meta Platforms. Our analysis of options history for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) revealed 59 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 23% showed bearish tendencies. Out of all the trades we spotted, 20 were puts, with a value of $1,154,122, and 39 were calls, valued at $4,876,072.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $640.0 for Meta Platforms during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Meta Platforms's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Meta Platforms's whale trades within a strike price range from $250.0 to $640.0 in the last 30 days. 
<h3>Meta Platforms Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731090754_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$186.85</td>
<td>$185.25</td>
<td>$186.55</td>
<td>$500.00</td>
<td>$708.8K</td>
<td>200</td>
<td align="right">150</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$150.0</td>
<td>$149.0</td>
<td>$149.79</td>
<td>$450.00</td>
<td>$299.5K</td>
<td>334</td>
<td align="right">76</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$148.95</td>
<td>$148.45</td>
<td>$148.75</td>
<td>$450.00</td>
<td>$223.1K</td>
<td>334</td>
<td align="right">51</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$24.55</td>
<td>$23.7</td>
<td>$24.4</td>
<td>$570.00</td>
<td>$195.2K</td>
<td>508</td>
<td align="right">667</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$29.95</td>
<td>$29.65</td>
<td>$29.95</td>
<td>$590.00</td>
<td>$179.7K</td>
<td>3.5K</td>
<td align="right">86</td>
</tr>
</tbody>
</table>

<h3>About Meta Platforms</h3>
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
<h3>Present Market Standing of Meta Platforms</h3>
<ul>
<li>Currently trading with a volume of 5,289,902, the META's price is down by -0.83%, now at $586.8. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<h3>What The Experts Say On Meta Platforms</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $665.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein persists with their Outperform rating on Meta Platforms, maintaining a target price of $675. 
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Meta Platforms, which currently sits at a price target of $811. 
&#x2A; An analyst from Roth MKM persists with their Buy rating on Meta Platforms, maintaining a target price of $620. 
&#x2A; An analyst from Scotiabank has revised its rating downward to Sector Perform, adjusting the price target to $585. 
&#x2A; Consistent in their evaluation, an analyst from Roth MKM keeps a Buy rating on Meta Platforms with a target price of $635. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Meta Platforms with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Decoding Meta Platforms's Options Activity: What's the Big Picture?

Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 48 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 35% leaning bullish and 50% bearish. Among these notable options, 36 are puts, totaling $7,149,868, and 12 are calls, amounting to $827,264.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $135.0 for Moderna, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Moderna stands at 2268.03, with a total volume reaching 22,831.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $30.0 to $135.0, throughout the last 30 days.
<h3>Moderna Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731090749_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$70.45</td>
<td>$70.45</td>
<td>$70.45</td>
<td>$120.00</td>
<td>$2.4M</td>
<td>980</td>
<td align="right">346</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$70.9</td>
<td>$69.7</td>
<td>$70.4</td>
<td>$120.00</td>
<td>$971.5K</td>
<td>980</td>
<td align="right">346</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$42.15</td>
<td>$41.0</td>
<td>$41.12</td>
<td>$85.00</td>
<td>$479.4K</td>
<td>1.1K</td>
<td align="right">517</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$70.35</td>
<td>$69.7</td>
<td>$70.35</td>
<td>$120.00</td>
<td>$443.2K</td>
<td>980</td>
<td align="right">564</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$82.85</td>
<td>$81.3</td>
<td>$82.85</td>
<td>$130.00</td>
<td>$314.8K</td>
<td>620</td>
<td align="right">290</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Moderna's Current Market Status</h3>
<ul>
<li>With a volume of 7,492,117, the price of MRNA is down -6.64% at $46.94. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 104 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MRNA

Smart Money Is Betting Big In MRNA Options

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on scPharmaceuticals (SCPH – Research Report), with a price target of $2...

TD Cowen Sticks to Its Buy Rating for scPharmaceuticals (SCPH)

Leerink Partners analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) yesterday and set a price target of $20....

Buy Rating Affirmed for scPharmaceuticals Amidst FDA Approval and Strong Financial Performance

scPharmaceuticals GAAP EPS of -$0.44 misses by $0.02, revenue of $8.05M beats by $0.08M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
scPharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/scph-stock-quote/">SCPH</a>) just reported results for the second quarter of 2024.<ul><li>scPharmaceuticals reported earnings per share of -44 cents. This was below the analyst estimate for EPS of -40 cents.</li><li>The company reported revenue of $8.05 million.</li><li>This was 0.44% worse than the analyst estimate for revenue of $8.09 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/scph-stock-earnings-scpharmaceuticals-for-q2-of-2024/">SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SCPH Stock Earnings: scPharmaceuticals Misses EPS, Misses Revenue for Q2 2024

scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript

Maxim Group analyst Naz Rahman reiterated a Buy rating on scPharmaceuticals (SCPH – Research Report) yesterday and set a price target of $20.00. Na...

Buy Rating Affirmed: scPharmaceuticals's Revenue Surge and Product Development Promise

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kronos Bio (KRON – Research Report), Spruce Biosciences (SPRB – R...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and scPharmaceuticals (SCPH)

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on scPharmaceuticals (SCPH – Research Report). The company's ...

Craig-Hallum Remains a Buy on scPharmaceuticals (SCPH)

Maxim Group analyst Naz Rahman has reiterated their bullish stance on SCPH stock, giving a Buy rating yesterday. Naz Rahman has given his Buy ratin...

Strategic Buy Rating for scPharmaceuticals: Furoscix's Potential in CKD Market

Roanna Ruiz, an analyst from Leerink Partners, maintained the Buy rating on scPharmaceuticals (SCPH – Research Report). The associated price target...

Strategic Growth and Market Expansion Opportunities Drive Buy Rating for scPharmaceuticals

KRON

SCPH

SPRB

Health Care

Press Releases

scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease

Comments

scPharmaceuticals

Vendite allo scoperto

scPharmaceuticals (NASDAQ:SCPH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO